High-grade serous ovarian cancer (HGSC) is common, with poor prognosis. Limited therapeutic options are available, and the development of new therapies is of high priority. The RNA Polymerase I (Pol I) transcription inhibitor ...

Oesophageal adenocarcinoma is an aggressive malignancy and is associated with extremely poor rates of survival. Its only known precursor is Barrett’s oesophagus, which is a metaplasia that occurs in the lower oesophagus ...

Multiple myeloma (MM) is a malignant plasma cell disorder that is incurable with currently available therapy. The disease is genetically heterogeneous, with many recurrently mutated genes only seen in small numbers of ...

The genetic causes of the majority of hereditary breast cancer families remain unresolved (BRCAx families) and lack of this information compromises primary and secondary cancer prevention for the affected women and their ...

The immune response is strongly associated with outcome in CRC (stages I-III). Cytotoxic CD8+ T-cells are the most important subset of immune cells positively associated with outcome, in most solid malignancies and especially ...

Mutations in the tumour suppressor gene, TP53 occur in more than 50% of human cancers. Mutant p53 proteins not only lose their tumour suppressive capacities, but also gain oncogenic functions, broadly referred to as gain ...

The ribosomal RNA (rRNA) genes (rDNA) are arrayed in multiple tandem repeats on the 5 acrocentric chromosomes, and are transcribed by RNA Polymerase I (Pol I) which gives rise to the 47S pre-rRNA, the precursor of 18S, ...

The predictive and prognostic significance of tumour infiltrating lymphocytes (TILs) has been highlighted in various solid cancers in recent years, where TIL infiltration has become a landmark biomarker of survival outcomes ...

Despite recent advances in cancer detection, molecular classification and treatment modalities, the 5-year survival rate of acute myeloid leukaemia (AML) has not changed in 30 years. The unique genetic context created by ...

Mantle cell lymphoma (MCL) is a B-cell malignancy and often an incurable disease. Novel targeted therapeutics are poised to significantly change the natural history of this disease. The combination of ibrutinib and venetoclax ...